20
Participants
Start Date
October 31, 2010
Primary Completion Date
March 31, 2012
Study Completion Date
December 31, 2012
2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia
Collaborators (1)
Pfizer
INDUSTRY
National Cancer Institute (NCI)
NIH
University of Pennsylvania
OTHER